CYHNYSEServices-General Medical & Surgical Hospitals, NECFiscal year ends December 31
COMMUNITY HEALTH SYSTEMS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$2.76−0.12 (-4.17%)
Close on Oct 19, 2026
- Market cap
- $376.75M
- P/E (TTM)
- 1.5
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
85.1%+1.7 pts over 5 years
Operating margin
11.9%+2.4 pts over 5 years
Net margin
4.1%−0.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -1.2% | +0.7% | +1.2% | – | |
| Gross profit | -0.6% | +1.2% | +1.6% | – | |
| Operating income | +174.5% | +21.9% | +5.7% | +1.1% | |
| Net income | – | +122.8% | -0.1% | +12.4% | |
| EPS, diluted | – | +120.8% | -3.0% | +10.7% | |
| Free cash flow | +73.3% | – | -34.6% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -61.1% | -26.6% | -30.8% | |
| Return on assets | -7.1% | 3.2% | 3.7% | |
| Current ratio | 1.62 | 1.60 | 1.46 | |
| Debt to equity | 9.44 | -7.52 | -7.46 | |
| Net debt to EBITDA | 62.52× | 6.26× | 5.30× | |
| Capex to revenue | 4.0% | 3.7% | 2.7% | |
| Diluted shares | 111M | 117M | 135M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Community Health Systems generated $1.66B from operations and spent $2.05B on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.66B
Used
$2.05B
Capital expenditure$2.05B100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin4.1%
×Asset turnover0.92×
×Equity multiplier-8.24×
=Return on equity, FY2025-30.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 4.1% | 0.92× | -8.24× | -30.8% |
| FY2024 | -4.1% | 0.89× | -8.62× | 31.2% |
| FY2023 | -1.1% | 0.86× | -10.56× | 9.6% |
| FY2022 | 0.4% | 0.82× | -10.91× | -3.4% |
| FY2021 | 1.9% | 0.79× | -10.42× | -15.3% |
| FY2020 | 4.3% | 0.75× | -8.23× | -26.6% |
| FY2019 | -5.1% | 0.84× | -8.38× | 36.0% |
| FY2018 | -5.6% | 0.85× | -14.47× | 68.5% |
| FY2017 | -16.0% | 0.78× | 46.46× | -580.0% |
| FY2016 | -9.3% | 0.76× | 8.62× | -61.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
8of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$509.00M
- Cash generatingOperating cash flow above zero$543.00M
- Return on assets improvedROA up on the prior year-3.6% → 3.6%
- Earnings backed by cashOperating cash flow above net income$543.00M vs $509.00M
- Less leverageLong-term debt to assets fell81.3% → 78.6%
- Better liquidityCurrent ratio rose1.41 → 1.46
- No dilutionShare count did not rise132M → 135M
- Gross margin improvedGross margin up on the prior year84.60% → 85.07%
- More efficientAsset turnover rose0.87 → 0.89